80,000 Stored Blood Samples Could Reveal Dementia and Parkinson's Years Before Symptoms
A UK Biobank study will measure rare brain proteins in 80,000 blood samples to find early signs of Alzheimer's and Parkinson's long before diagnosis.
Summary
UK Biobank has launched UKB-PRISM, a study that will measure hundreds of circulating proteins in 80,000 stored blood samples to look for early warning signs of Alzheimer's disease, Parkinson's disease and rare dementias. The proteins that signal a failing brain are hard to detect because they circulate at very low levels. The work uses Alamar Biosciences' NULISA platform, run in Nightingale Health's laboratories. Because the samples were collected years or even decades before many participants were diagnosed, and are linked to genetics, imaging and medical records, researchers can test whether these proteins predict who later became ill and when disease began. The study is funded by the Michael J Fox Foundation, Alzheimer's Research UK and LifeArc, and should finish by the end of 2027. Data will be open access. A protein that tracks with later disease is not yet a usable test, and UK Biobank participants are healthier and less diverse than the general population.
Detailed Summary
Dementia and Parkinson's disease are among the largest threats to healthy aging. More than 55 million people live with Alzheimer's and other dementias, a number expected to nearly triple by 2050, while Parkinson's affects over 12 million and may pass 25 million in the same period. The biology of these diseases starts long before symptoms, yet the earliest protein signals are hard to catch in blood because they exist at very low concentrations.
UKB-PRISM (Proteomics for Risk Identification and Signatures of brain health in Midlife) aims to change that. It will measure hundreds of circulating protein biomarkers in 80,000 stored UK Biobank blood samples using Alamar Biosciences' NULISA platform, run in Nightingale Health's laboratories. Nightingale has already generated metabolomic data on all 500,000 participants, so the new protein layer will sit on top of existing chemistry. The Michael J Fox Foundation, Alzheimer's Research UK and LifeArc are funding the work, which covers Alzheimer's, Parkinson's and rare dementias and is due to finish by the end of 2027.
The key advantage is timing. Samples were taken years, sometimes decades, before many participants were diagnosed, and each is linked to genetics, imaging and medical records. That lets researchers ask whether protein patterns in people who were well can identify who later developed disease, and when the process truly began. The study will also examine Alzheimer's and Parkinson's together, as conditions that may share biological roots. Open access means independent groups can check the results. The project is described as a vanguard, a test of whether brain-focused proteomics should be extended across the whole cohort.
For readers, this is a research program rather than a test you can take today. If successful, it could lead to blood-based screening that detects risk in midlife, when interventions may have the most effect.
Caveats matter. A protein associated with later disease is not automatically a validated diagnostic. UK Biobank is healthier, wealthier and less diverse than the wider population, which may limit generalizability. Both companies involved also benefit commercially from the visibility. No results have been reported yet.
Key Findings
- UKB-PRISM will measure hundreds of blood proteins in 80,000 stored UK Biobank samples for early signs of neurodegeneration.
- Samples predate diagnosis by years or decades, allowing tests of whether proteins predict later dementia or Parkinson's.
- The NULISA platform is designed to detect very low-abundance brain proteins that most assays miss.
- The study will examine Alzheimer's and Parkinson's together to look for shared biological roots; data will be open access.
- No results yet: findings are due by end of 2027, and biomarkers are not validated clinical tests.
Methodology
This is a news report with editorial commentary on a newly announced study, quoting UK Biobank, Alamar and Nightingale executives. No data or results are presented, so the evidence basis is the study design and stated aims. Quotes come from the organizations involved, who have commercial or institutional interests.
Study Limitations
The study has just been announced and no findings exist, so claims about early detection are aspirational. UK Biobank skews healthier, wealthier and less diverse, limiting generalizability, and association with later disease does not equal a validated test. Check the primary UK Biobank and company announcements and, later, peer-reviewed results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: